text:
I can't seem to shake off the feverish feeling I've been having over the last 2 weeks - which skyrocketed over the weekend. Those rumblings deep down in your stomach which cannot and should not be mistaken for the butterfly feeling that accompanies love (or lust). The occasional goose pimples that crawls on your skin … Continue reading Nostalgia of saying goodbye – P&G, it was nice knowing you!
Month: July 2012
Job Searching – On a lighter note!
One of the things you'd be thinking of mid-way into your MBA program will be getting the dream job - if such exists - you've always wanted. The above picture, which I got from a colleague on FB, describes a very funny way to figure out what job suits you. In the last … Continue reading Job Searching – On a lighter note!
Why I was dinged at Harvard Business School
Someone asked me why I was telling people about my being dinged at Harvard and probably you are also wondering why I am. My ultimate intention with this blog is to inspire other Africans like myself, not with what I can achieve but rather, with what is basically achievable. And empower them to dare to … Continue reading Why I was dinged at Harvard Business School
Why I applied to Harvard Business School!
Like I mentioned in an earlier post, HBS was one of the schools I applied to, however, I was dinged and I remember mentioning that it was for obvious reasons. Well, before telling you why I think I got dinged, I want to lay out my reasons for applying to HBS. In other posts, I … Continue reading Why I applied to Harvard Business School!
Myths about MBA Program busted
You probably have heard so much about doing an MBA. Trust me, I have heard and read much more! Including the risk! But is life without risks? So I culled up some myths about the MBA program and provided some perspective on them below. Feel free to challenge any of the myths below and let's … Continue reading Myths about MBA Program busted


text:
My chubby wife has been famous for her heavy petting sessions while french kissing.. Her special trick has been masturbation by thigh squeezing. The boys liked her panting and body squirming at the end. Only a very few she allowed to touch her slimy slippery quim. She had orgasms in a row often and onlookers.
jeg er kat...
I just wanted to point out that when it comes to pelvic floor health, it's important to balance your kegels with squats.
nice fanney
The music makes it sound like a really stupid magic trick
Actually it is my own lingerie ;)

subset: commoncrawl


text:
Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting.
Docetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed.
From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9~4.0) and 2.8 months (95% confidence interval: 1.0~4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths.
A meta-analysis of the published data has shown a modest, but significant survival benefit for platinum-based chemotherapy and supportive care as compared to best supportive care alone for patients suffering with non-small cell lung cancer (NSCLC)1). Platinum-based chemotherapy has been regarded as a standard treatment for patients with advanced NSCLC. However, the importance of second-line treatment has been highlighted in research because most NSCLC patients fail to respond to a front-line regimen. Several reports have suggested that docetaxel2, 3) or pemetrexed4) are optimal regimens as second-line treatment.
The administration of docetaxel (Taxotere®; Aventis Pharmaceuticals Inc.; Bridgewater, NJ), every 3 weeks at doses of 75~100 mg/m2 in phase II trials5, 6) has resulted in a response rate of 16%~22% and a survival period of 6.9~9.7 months. Two phase III trials (the TAX3172) and TAX 3203)) displayed the superiority of docetaxel at 75 mg/m2 for disease/symptom control, survival and the quality of life, and this was despite the relatively low response rate of 5.5~6.7% when compared to the best supportive care or an alternative single-agent such as vinorelbine or ifosfamide. In spite of these promising results, there were severe docetaxel-induced toxicities. Grade 3-4, severe neutropenia occurred in 85.7% of the patients in the 100 mg/m2 arm and in 67.3% of the patients in the 75 mg/m2 arm of the TAX 317 trial2). In the TAX 320 trial3), the frequency of neutropenia was significantly greater in the docetaxel group (54%) as compared to the vinorelbine/ifosfamide group (31%). Considering the recent steep increases in the incidence of elderly patients or patients with a poor performance status (PS) who fail with first-line chemotherapy7), it seems that a 3-week schedule of docetaxel would be difficult to applied to these specific populations in a clinical setting.
A weekly schedule may enable the delivery of repeated effective doses with minimal toxicity, which would lead to achieving increased drug dose intensity and maximized efficacy. Weekly schedules with the newer chemotherapeutic agents, such as paclitaxel8, 9) and docetaxel10-13), have recently been intensively tried in advanced NSCLC patients. The phase II and III trials that have compared a weekly schedule with a 3-week schedule have demonstrated that a weekly schedule could significantly reduce grade 3-4 neutropenia by 2~20% with similar therapeutic efficacy10-13).
We retrospectively compared the efficacy and toxicity of weekly docetaxel to those of a standard 3-week regimen as second-line chemotherapy for patients suffering with advanced NSCLC.
Patient's eligibility
The eligible patients for this study were treated from October 2003 to March 2006 at Kangnam St. Mary's Hospital, and they were required to have histological or cytological proof of having stage IIIB or IV NSCLC, and they had least one bidimensionally measurable lesion outside the previously irradiated area and they had received only one prior platinum-containing chemotherapy regimen. The patients were also required to have a minimum ECOG performance status of (PS) ≤2 and adequate physiological organ functions: 1) hepatic function (a normal bilirubin level, a normal asparate aminotransferase level and a normal alanine aminotransferase level ≤1.5 the upper limit of normal (ULN) and an alkaline phosphatase level ≤5 ULN), 2) renal function (a serum creatinine level ≤1.5 ULN) and 3) hematological function (an absolute neutrophil count ≥ 2×109/L, a platelet count ≥100×109/L and a hemoglobin level 10 g/dL).
Treatment schedule
Docetaxel was administered on a 3-week or weekly schedule. Three-week schedules were conducted from October 2003 to September 2004 and then weekly schedules were conducted from October 2004 to March 2006. For the 3-week docetaxel administration regimen, docetaxel 75 mg/m2 was given intravenously on day 1 of a 21-day cycle, whereas during the weekly regimen, docetaxel 37.5 mg/m2 was administered intravenously on days 1 and 8 of a 21-day cycle. Docetaxel was administered intravenously as a 1-h infusion, whereas premedications (dexamethasone 8 mg twice daily (orally) the day before chemotherapy and immediately after docetaxel infusion, and ranitidine 50 mg, diphenhydramine 50 mg and 5-hydroxytryptamine 3 receptor antagonist) were administered at the same dosage for each schedule. Docetaxel was discontinued if a patient experienced disease progression, irreversible grade 3/4 toxicity or wanted to discontinue the treatment. Chemotherapy was postponed until attaining recovery of the bone marrow function. The investigators determined to continue the consecutive chemotherapy when the patients experienced an objective decline in their performance status.
Efficacy and toxicity
The patients were evaluated using computed tomography for determining the anti-tumor efficacy according to the WHO criteria at every 2 cycles. A complete response (CR) was defined as the disappearance of all tumor lesions. A partial response (PR) was defined as an estimated ≥50% decrease in tumor size with no detectable new lesions. Progressive disease (PD) was defined as the appearance of any new tumor lesions or a ≥25% increase in the size of the existing tumor lesions. When the responses did not qualify as CR, PR or PD, then they were reported as stable disease (SD). Toxicity was assessed on days 1 and 8 of a 21-day cycle for the weekly regimen and on day 1 of a 21-day cycle for the 3-week regimen. The toxicity was graded using the NCI CTC version 2.0.
The overall survival (OS) duration was defined as the time between the date of starting treatment and the date of the last follow-up or death. Time to progression (TTP) was defined as the time between the date of starting treatment and the date of progressive disease. The response duration was calculated from the day of the observed response until the day of documented progression. The disease control rate was defined as the proportion of patients with a partial or complete response to an investigational treatment plus those patients for whom their disease had stabilized. The durations of the OS and TTP were estimated using the Kaplan-Meier method and the differences between the Kaplan-Meier curves were evaluated by the log-rank test.
Patients' characteristics
Our retrospective study included 37 patients who received docetaxel monotherapy as a second-line treatment between Oct 1, 2003 and March 31, 2006. One patient on the weekly schedule was excluded due to loss of follow-up. The patients' characteristics are summarized in Table 1. Eighteen patients received weekly administration of docetaxel, whereas 19 patients received a 3-week administration schedule of docetaxel. The median patient age was 64 (range: 41~69) for the weekly schedule and 63 (range: 33~70) for the 3-week schedule. The patients' gender ratio was similar for both the weekly and 3-week schedules. The patients with an ECOG PS of 2 or those with stage IV disease were examined more frequently during the 3-week schedule. The histopathology most frequently revealed adenocarcinoma, which was more common for the 3-week schedule (89.5%) than for the weekly schedule (55.6%). Thirty-three patients (89.2%) received platinum-based chemotherapy as a first-line treatment, and a combination of gemcitabine/cisplatin was the most common chemotherapy. Seven patients (38.9%) from the weekly schedule and 10 patients (52.7%) from the 3-week schedule responded to first-line treatment. Of the 37 patients in this study, nine had chronic diseases, five had hypertension and three had diabetes mellitus. The median time from diagnosis to initiation of docetaxel was 7.1 months (range: 1.9~74.1). A total of 135 chemotherapy cycles were administered with the median number of cycles/patient being 3.0 (range: 1~9).
Treatment efficacy
A response evaluation was assessed for a total of 37 patients. The objective response rate was 16.7% (95% confidence interval: 0~36.0) for the weekly schedule and 21.1% for the 3-week schedule. Disease control was achieved in 10 patients (55.6%) for the weekly schedule and in 12 patients (63.2%) for the 3-week schedule. The length of response was a median of 2.2 months (range: 0.7~3.9) for the weekly schedule and 2.6 months (range: 0.2~7.6) for the 3-week schedule (Table 2). The median overall TTP was 2.8 months (95% confidence interval: 2.3~3.3) with a median TTP of 3.0 months (95% confidence interval: 1.9~4.0) for the weekly schedule and 2.8 months (95% confidence interval, 1.0~4.6) for the 3-week schedule. No significant differences were observed between the two different treatment schedules (p=0.41) (Figure 1). The median OS time was 12.0 months (95% confidence interval: 5.9~18.1) for all the patients with a median OS of 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and a median OS of 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule. The 2.6 months difference in the OS between the 2 groups was not statistically significant (p=0.41) (Figure 1). Out of the 24 patients (weekly schedule: 3 males and 6 females, 3-week schedule: 4 males and 7 females)who had been on a third-line therapy after docetaxel therapy, 20 received an EGFR tyrosine kinase inhibitor (TKI), and the remaining four were treated with gemcitabine/vinorelbine combination chemotherapy.
Toxicity was quantifiable in all 135 cycles and the treatment-linked severe toxicities including grade 3 or more neutropenia (25.2%), which occurred much more frequently in the 3-week schedule (28 cycles, 38.9%) as compared with the weekly schedule (6 cycles, 9.5%). Febrile neutropenia was observed during 2 cycles for the weekly schedule and this was observed during 4 cycles for the 3-week schedule. Grade 3 or more anemia occurred in only 2 cycles and no severe thrombocytopenia was observed. The non-hematologic toxicities were generally mild and they primarily included peripheral neuropathy (101 cycles, 74.8%), asthenia (49 cycles, 36.3%) and oral mucositis (45 cycles, 33.3%). Moreover, grade 3 or greater peripheral neuropathy occurred during three cycles (4.8%) of the weekly schedule and during one cycle (1.4%) of the 3-week schedule. Interstitial lung disease (ILD) was found in five cases, and one of these cases displayed grade 3 peripheral neuropathy (Table 3). ILD was diagnosed by high-resolution computed tomography and also with excluding the infectious causes. Administration of chemotherapy was postponed in 19 cycles. However, there was no justification to reduce the chemotherapy doses. The administered docetaxel dose intensity (D.I.) for the weekly schedule was 96% of the planned D.I. (25 mg/m2/week) and it was 95.6% for the 3-week schedule. Moreover, there was no treatment-related mortality; during the median follow-up of 8.7 months (range: 1.8~3.6) for 37 patients, 23 patients died of cancer progression and one patient died of a cerebrovascular event.
Platinum-based regimens have been the mainstay of lung cancer chemotherapy since a meta-analysis in 1995 demonstrated their statistically significant survival benefit over the best supportive care alone for treating advanced NSCLC1). Those advanced NSCLC patients who exhibit disease progression or local relapse after first-line chemotherapy may be candidates for second-line treatment. Two drug combination regimens have shown increased toxicities without any survival benefits, and the increased toxicity has sometimes led to toxicity-related deaths. Consequently, single-agent chemotherapy has been actively attempted, and this has become the preferred treatment option in a second-line setting14). Of the newer cytotoxic drugs that are used for treating NSCLC, gemcitabine, vinorelbine, taxane and pemetrexed monotherapy have been widely explored for treating NSCLC patients who failed their front-line treatment. Docetaxel monotherapy in the previous phase II studies has demonstrated promising results with a response rate of 16~22% and a median survival of 6.9~9.7 months5, 6). The phase III trials have shown statistically greater differences of the median survival time (5.7~7.5 months), the 1-yr survival rate (32~37%) and the quality of life in comparison to the control groups (the best supportive care, or vinorelbine or ifosfamide monotherapy), and this is despite the low response rates (less than 10%)2, 3). Vinorelbine3), paclitaxel9) and gemcitabine15) monotherapy have shown response rates of 20%, 0.8% and 14%, respectively, and a median survival duration of 5.5 months, 5.6 months and 3.7 months, respectively. However, these drugs have not been accepted as standard second-line chemotherapy for advanced NSCLC patients because of the poor clinical outcome compared to docetaxel monotherapy3, 9). A large-scale randomized phase III trial has recently compared pemetrexed and docetaxel as second-line monotherapy treatments, and the results have indicated similar efficacy and significantly improved safety4).
The TAX320 study was a 3-arm, phase III randomized trial that compared docetaxel (100 mg/m2 to start and then 75 mg/m2 every 3 weeks) and a "standard" arm of either vinorelbine or ifosfamide3). This trial established the superiority of docetaxel, at the intermediate dose of 75 mg/m2, for the response rate, the time to progression and the overall survival of the study patients. Shim et al. reported that 75 mg/m2 of docetaxel monotherapy every 3 week was also effective in a Korean population with a response rate of 18.2% and a median survival time of 11 months16).
Despite these promising results, docetaxel-associated toxicity is known to be a significant factor during therapy. In the TAX 320 trial3), the occurrence of grade 3 or more neutropenia was more frequent (54%) for the docetaxel 75 mg/m2 group compared to that of the vinorelbine or ifosfamide group (31%). In the effort to reduce the hematologic toxicities of the 3-week administration schedule, four randomized trials were conducted with using different dosages and schedules of the standard treatment. In a phase II trial conducted by Geravis et al10), similar efficacy was observed between a weekly schedule and 3-week schedule of docetaxel monotherapy with response rates of 3.2% and 4.8%, respectively, a median survival duration of 5.8 months and 5.5 months, respectively, a 1-yr survival rate of 6% and 18%, respectively. Moreover, several phase III trials have shown a response rate of 5.5~10.5% and 2.7~12.6%, respectively, and a median survival duration of 6.1~9.2 months and 5.8~6.7 months, respectively, for the weekly and 3-week regimens of docetaxel monotherapy11-13). In our study, there were no significantly differences in efficacy between the weekly and 3-week regimens with response rates of 16.7% and 21.1%, respectively. (p=0.57), median TTPs of 3 months and 2.8 months, respectively (p=0.41) and median OSs of 13.3 months and 9.3 months, respectively (p=0.41), for the weekly and 3-week regimens. Although the 3-week regimen group included more female patients and more adenocarcinoma patients, the proportion of female adenocarcinoma patients (54.5%) who received EGFR TKI as a third-line treatment was similar to that of the weekly regimen group (44.4%). In addition, several pharmacokinetics (PK) studies have provided data that the PK parameters, including the half life, clearance and area under the concentration-time curve (AUC) were similar between the weekly and 3-week schedule17, 18). Baker et al. have reported that the plasma concentration of docetaxel was maintained as 0.5 nM for 21 days in the 3-week docetaxel group and the plasma concentration was measured in the weekly group as 1.0 nM for the whole 7 day period after its administration17). It has been suggested that the anti-tumor efficacy of taxanes come about both by inhibiting the mobility of microtubules and the anti-angiogenesis effect at a relatively lower intracellular concentration19, 20). These data support the clinical results of weekly docetaxel monotherapy.
In a randomized phase III trial12), Scheutte et al. reported that a weekly docetaxel regimen was unlike the 3-week regimen with respect to the toxicity profile. The incidence of grade 3 or more neutropenia and anemia were 4.8% and 1.0%, respectively, in the weekly arm compared to 20.6% and 5.9%, respectively, in the 3-week arm. In our study, the incidence of grade 3 or more neutropenia in the 3-week arm and the weekly arm concurred with these previous findings (38.9% and 9.5%, respectively, in our study). Because polysorbate 80, which is a vehicle for docetaxel, competes with docetaxel itself for binding plasma α-1-acid glycoprotein, a higher dose of docetaxel may give rise to an increased plasma concentration of the unbound form21). Past studies have shown that the pharmacokinetics of the unbound forms, rather than that of the total docetaxel, are more closely correlated with the incidence and severity of neutropenia due to docetaxel administration22). Although the reason for the different toxicity profile has not been clearly determined, the above facts could be one of the possible explanations. In contrast to the clinical trials that used docetaxel in a first-line setting, the most common non-hematologic toxicity in our study was peripheral neuropathy, and this was seen in 74.8% of the patients. This finding might be associated with an accumulation of peripheral nerve injury by platinum because most of the patients had received platinum-based chemotherapy as a first-line treatment. Other toxicity symptoms included asthenia, oral mucositis and gastrointestinal symptoms. No difference was observed for the non-hematological toxicities between the two groups, except for peripheral neuropathy. In addition, severe peripheral neuropathy over grade 3 occurred more frequently in the patients of the weekly regimen (4.8%) as compared to that of the patients of the 3-week regimen (1.4%). In the CALGB 9840 study that compared paclitaxel 80 mg/m2 weekly (n=234) with 175 mg/m2 every 3 weeks (n=230) for treating advanced breast cancer patients, a severe sensory type of peripheral neuropathy (over grade 3) occurred in 19% of the patients of the weekly group and in 12% of the patients in the 3-weeks group (p=0.001)23). However, there was no significant difference of peripheral neuropathy between the schedules in the phase III trials of NSCLC that compared weekly docetaxel with 3-week docetaxel11, 13). With regard to pulmonary toxicity, ILD was found in five cases (3 weekly cases and 2 3-week cases). All the cases developed ILD 1 month after therapy had begun. In one case, a lung biopsy finding showed bronchiolitis obliterans/organizing pneumonia; infiltration of mononuclear cells into the alveolar septa and interstitial fibrosis was observed in 2 cases. Even though serious ILD of more than grade 3 was observed in one weekly regimen case, this patient recovered after steroid treatment. The co-morbid diseases afflicting the study patients included diabetes mellitus with nephropathy, COPD and decreased pulmonary function after previous lobectomy. Three cases received gemcitabine/cisplatin, one case received etoposide/cisplatin and another case received paclitaxel-based concurrent chemoradiotherapy as first-line chemotherapy. We cannot make conclusions about the relationship between the administration schedule and the non-hematologic toxicities (e.g., peripheral neuropathy, ILD, etc.) with such a small sample size.
Our study is limited by a small patient sample size, and their quality of life or their satisfaction with the treatment could not be evaluated because of the study's retrospective nature. Despite these limitations, this study affirmed that the weekly regimen of docetaxel monotherapy has an equally favorable toxicity profile compared to the 3-week schedule. This study supports that a weekly schedule of docetaxel monotherapy is a reasonable alternative for those NSCLC patients who fail with first-line platinum-based chemotherapy.
1. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995. 311:899–909PMID : 7580546.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Brukes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000. 18:2095–2103PMID : 10811675.
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. The TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 2000. 18:2354–2362PMID : 10856094.
4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Geravis R, Sharharyar , Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004. 22:1589–1597PMID : 15117980.
5. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small-cell lung cancer. J Clin Oncol 1995. 13:645–651PMID : 7884425.
6. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000. 18:131–135PMID : 10623703.
7. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997. 33:2313–2314PMID : 9616273.
8. Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, Gomi K, Koinumaru S, Saijo Y, Nukiwa T. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2006. 52:83–87PMID : 16483687.
9. Esteban E, Gonzalez de Sande L, Fernandez Y, Corral N, Fra J, Muniz I, Vieitez JM, Palcio I, Fernandez JL, Estrada E, Lacave AJ. Prospective randomized phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum based chemotherapy. Ann Oncol 2003. 14:1640–1647PMID : 14581272.
10. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Coulet P, Quoix E. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second line therapy in patients with advanced non small cell lung cancer (NSCLC). Ann Oncol 2005. 16:90–96PMID : 15598944.
11. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Poantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Babera S, Perrone F. A randomized clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second line treatment of non-small-cell lung cancer. Br J Cancer 2004. 91:1996–2004PMID : 15558071.
12. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Phase III study of second line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3 weekly docetaxel. J Clin Oncol 2005. 23:8389–8395PMID : 16293869.
13. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Amenar D, Blasco A, Rosell R, Carrato A, Vinolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E. Randomized phase III study of 3 weekly versus weekly docetaxel in pretreated advanced non small cell lung cancer. Ann Oncol 2006. 17:467–472PMID : 16371411.
14. Barlesi F, Jacot W, Astoul P, Pujol JL. Second line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 2006. 51:159–172PMID : 16360238.
15. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S, Gatani T, Fiore F, Guida C, Scognamiglio F. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999. 19:4535–4538PMID : 10650806.
16. Shim BY, Jim CH, Song SH, Ahn MI, Hong EJ, Kim SW, Kim S, Jo MS, Cho DG, Cho KD, Yoo J, Kim HK. The safety and efficacy of second-line single docetaxel (75 mg/m2) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum based chemotherapy. Cancer Res Treat 2005. 37:339–343.
17. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carduci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004. 10:1976–1983PMID : 15041715.
18. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998. 16:187–196PMID : 9440742.
19. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001. 61:3369–3372PMID : 11309294.
20. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001. 20:3806–3813PMID : 11439344.
21. Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002. 773:183–190.
22. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003. 74:364–371PMID : 14534523.
23. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Naughton M, Norton L, Winer E, Hudis C. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1 hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004. 22:6s. (suppl 14; abstr 512).
Table 1
Table 2


text: Request A Visit If you need to have a pastor or someone from the church to visit you or a loved one, please use the form below. Name of Person To Be Visited: *Contact Phone Number *Type of Visit *HospitalHomeLocation Information *Please provide the Address of the Home or the Name and Address of the Hospital with Room Number:Requested Time For Visit? *Please provide an approximate time for the visit (include am or pm)Other Notes For Visit: *Please provide and other notes around the requested visit (illness, surgery, baby, etc.)NameSubmit


text:
STARmeterSEE RANK
Down 27,532 this week
Roldano Lupi (1909–1989)
Roldano Lupi was born on February 8, 1909 in Milan, Lombardy, Italy. He was an actor, known for Hercules Against the Barbarians (1964), Hero of Rome (1964) and The Story of the Count of Monte Cristo (1961). He died on August 13, 1989 in Rome, Lazio, Italy. See full bio »
Born:in Milan, Lombardy, Italy
Died:(age 80) in Rome, Lazio, Italy


text:
Software-defined Gateways for IoT World Connectivity
Internet of Things solutions require that sensors, devices, equipment and appliances can be connected to the Internet. There are many different wireless and wired protocols to consider – Bluetooth, Bluetooth LE, ZigBee, Z-Wave, WiFi, 6LoWPan, EnOcean, ModBus, to mention a few. On top of that there are several IoT Resource and Device Adaption frameworks like IoTivity and AllJoyn. Several different messaging protocols like MQTT, AMQP and XMPP are around.
An application developer are faced with several problems that cause headache. Firstly, they need to master several different technologies and go through framework specific APIs. Secondly, applications developed for one framework will not work in another framework. Thirdly, the data collected and the actions provided by devices needs to be mapped to the application business model. Applications are written from a business point-of-view, where the objects are "Robot", "Manufacturing Cell", "Line", "Shop Floor" while sensors and devices produce events like "Meter56223" and can be controlled using commands like "Move Axis X1 to Position 5".
The solution to these problems are a software-defined gateway, a concept being innovated by CNet through the LinkSmart .net software gateway. It acts as a bridge between the digital world and the physical world, allowing applications and apps to talk to, control and observe objects in the physical world through a common software gateway.
The Linksmart .net gateway provides mechanisms for routing requests regarding the physical world to the appropriate software resource that is able to fulfil the request, such as reporting the temperature in a particular office space or the current electricity consumption of an household appliance.
The gateway also provide means to detect and act on events that takes place in the physical world, such as a door was closed. Observations and state changes in the physical world can be logged and reported locally or to the cloud, thus providing the necessary facilities to create and make use of big data.
The fact that Linksmart.net is a software-defined gateway makes it very flexible and your applications future-proof and independent of changes to hardware and low level protocols. The Linksmart.net gateway is fully programmable and available as Open Source. Visit the IoTWorldServices to learn more and download.
A set of developer tools are available to allow configuration and administration of your IoT World.


text:
Daily Fishing Report.
In Summary:
Send all questions and pictures to email@example.com
Surf Fishing Report:
The rain left us about noon yesterday and though it was slow fishing, there were Sea Mullet scattered.
The winds are NW at 12 and the water temp is 63 degrees. Besides it being another morning of rain, and not much to report, I turned a big cup of black coffee over on a very light beige carpet. Is this a good day or WHAT!
Sound Fishing Report:
The Little Bridge on the Nags Head/Manteo causeway reported not much.
Pier Fishing Report:
Avalon: Blues and Sea Mullet.
Nags Head: Slow, small Trout and Sea Mullet.
Jennette's: Sea Mullet, Blues and Northern Puffers.
Outer Banks: Big Mullet, Blues and 1 Spanish.
Inshore Boats/nearshore Report:
Some inshore boats caught some nice Trout, small Stripers and Flounder.
Offshore Boats Report:
Big boats stay at the Docks.


text:
The Things You Got To Do In Desaru
Find out about Desaru?
Always how you spend your weekend? Hiding in the bedroom? Netflix? Shopping around? Or sleeping? It's so boring. Come to have a great time at Desaru. The majority of us was clueless that Desaru is in fact fun until we visit. Find out more about Desaru attractions here and you should know why it's worth to visit here, also Desaru beach resort together with the food there.
For you & your family
Hard Rock Hotel Desaru Coast is one of the best resort in Desaru. Well-known as being a family-friendly resort, they supply extraordinary amenities and entertainment that is definitely made for everyone, for example, Hard Rock Roxity Kids Club, pool party and daily live music. Furthermore, they offer a variety of rooms and suites to fulfill your desire.
If you prefer a hotel, you should consider the Amansari Hotel Desaru. It is a good location which is nearby to Desaru beach, for that reason, it is easy to look for a restaurant test local food and seafood. Aside from that, they supply laundry service and luggage storage which is definitely convenient for the traveler.
Looking for excitement?
If you are hoping for something excitement and fun, Desaru Coast Adventure Waterpark won't let you down. Specially created to 5 unique zones which satisfy the wish of all, make sure all the guest will have a great experience here. Bring about your family members or friend to have fun together. Book the tickets through the website.
Challenging outdoor activities
Desaru Ostrich Farm has over 100 of ostriches. The visitors have a chance to be close and play together with the ostriches. Ostrich's caretaker will be sharing everything regarding the ostriches for everyone. Also, there are various crafts selling on the farm. You can buy it as souvenirs to your friend and family!
Have you ever seen a firefly? No? Then you must visit Kota Tinggi Firefly Park. All the resources in Kota Tinggi are protected so you can have a great time in this great environment. The boat tour started at 7 pm. By the tour, you will see countless fireflies around the trees!
The favorite seafood corner
Seafood is regarded as the famous food in Desaru. With lots of seafood restaurant there, choosing which one to select is truly difficult. Don't worry! Just try Jade Garden Seafood Corner. The restaurant is 30 minutes away from Desaru Beach. Every seafood is fresh and delicious, also, at a low price.
Another suggestion for you is Sengat Seafood Restaurant. For the Muslim out there, you can enjoy delicious seafood here. It's nearby to Teluk Sengat Crocodile Farm. Spicy lovers must order their chili crab while salted egg lovers must order their salted egg crab. One additional thing is, the charge is affordable.
Eager to try it out?
Are you attract by all of the fun things in Desaru? If yes, get up and plan your own trip now. One tip here, if you plan for a family trip, do pick Hard Rock Hotel Desaru Coast since it is much more comfortable and family-friendly.
You can check out the website at https://www.hardrockhotels.com/desaru-coast to see the amenities and entertainments that they offer.


text:
Get Closer to the Asian Games with Canon
Canon invites the public to capture the spirit of the Asian Games
from 18 August to 2 September
Canon announced today activities to bring the visitors and at-home fans closer to the 18th Asian Games. In the spirit of the Games, Canon is bringing the 180-degree GIF booth to Jakarta for the Canon Experience Center located at the Kaka Festival Area, Gelora Bung Karno (GBK) Sports Complex. Canon has also set up 9 prime photo spots to help spectators get closer to the action at GBK, while Canon Touch and Try booths in 3 key locations let visitors try Canon's latest cameras and printers in between the action. For fans across the region, a photo competition on Instagram is ongoing from 18 August to 2 September to celebrate the spirit of sportsmanship and unity during the Asian Games.
Canon has been a fixture in major international sporting events, from the Olympics to the Southeast Asian Games.
"We are delighted to play a part in capturing the energy, the historic moments, and the stories behind talented and diverse athletes competing in the spirit of sportsmanship and unity at the 18th Asian Games," said Ms Noriko Gunji, President and CEO, Canon Singapore. "The Asian Games is particularly meaningful as an occasion for our Asian neighbours to gather and celebrate this quadrennial experience, and we want to bring spectators closer to the Games, whether they are in the stadium or watching from home."
To enhance the fun factor, Canon is bringing the 180-degree GIF booth to the Canon Experience Center at the Kaka Zone of the Gelora Bung Karno. Powered by 12 Canon EOS 1300D DSLRs, visitors can take home their own piece of the action and share their Asian Games experience on social media. The center also features the latest Canon consumer products, and a print center where fans and visitors are welcome to print their photos, schedule of the Games, as well as a map to the best photo spots at the various venues of the Asian Games.
Canon has arranged for 9 different Canon Photo Spots for the best vantage point to take photos of key events, located in several facilities across GBK Sports Complex:, Aquatic Center, Rugby Field, Baseball Stadium, and Istora (Badminton Hall).
Canon has also set up Touch and Trial booths at three key locations: Aquatic Center, Basketball Hall, and Istora (Badminton Hall). Visitors can zoom closer to the sporting action through Canon's cameras and binoculars.
Spectators at home can also get in on the action with the #CanonAsianGames18 Asia-wide Instagram photo competition hosted by @CanonAsia. To celebrate the spirit of sportsmanship and unity during the 18th Asian Games, Canon is inviting everyone to share how their community celebrates the #AsianGames2018 for a chance to win prizes from Canon.
Favorite Photo
3 Favorite Winners. Each gets one unit of Canon Selphy CP1300
Best Photos
1st Prize : EOS 80D kit (EF-S18-55 IS STM)
2nd Prize : EOS M50 kit (EF-M15-45 IS STM)
3rd Prize : PowerShot G7 X Mark II
For details of the contest and additional information about Canon's participation at the 18th Asian Games, visit https://www.canon-asia.com/asiangames/
Details of Canon Instagram Photo Competition
How to participate:
1. Follow @CanonAsia on Instagram.
2. Set your profile to "Public".
3. Capture and upload photo(s) that show how your community unites to celebrate the sporting spirit of the Asian Games. Tell us the story behind your photo with caption of up to 100 words, ending your description with #CanonAsianGames18 #AsianGames2018.
4. Tag @CanonAsia in your photo(s)
Terms and conditions and additional information can be found on https://www.canon-asia.com/asiangames/


text:
Chemical and Lead Isotope characterisation of First World War shrapnel balls and bullets used on the Alpine Austrian–Italian Front
Chemical and lead isotope characterisation was carried out on shrapnel balls and bullets dating back to the First World War (WWI). These ammunitions were widely utilised in the Alpine Austrian–Italian front located in the Italian Alps. The investigation has been performed using inductively coupled plasma quadrupole mass spectrometry equipped with an octopole reaction system (ORS-ICP-QMS). The main goal of this work was to identify the elemental and lead isotope composition of raw materials and to discriminate between the military objects analysed. The results of multi-elemental analysis indicate that the shrapnel ball samples consisted of soft Pb or hard Pb with Sb depending on the use, the weapon type and the specific nation. The Italian shrapnel balls were made from hard Pb, as opposed to those of the Austrian–Hungarian samples. Through the investigation of lead isotope ratios, it has been possible to differentiate most of the Italian shrapnel balls from those of Austrian–Hungarian origin. Furthermore, some Italian shrapnel balls had a different lead isotope composition depending on their calibre. The elemental composition and lead isotopic signature of bullets show a clear discrimination between the external jacket and the core in relation to projectile type and nationality. The bullet cores consist of Pb–Sb alloy regardless of the region of origin. This work allowed us to investigate the potential applications of trace elements and lead isotope analyses to discriminate military artefacts of different origins.
Full Text:PDF
DOI: https://doi.org/10.5787/46-1-1230
- There are currently no refbacks.
Copyright (c) 2018 Vittoria Latterza, Veronica Ros, Clara Turetta, Jacopo Gabrieli, Warren RL Cairns, Eleonora Balliana, Carlo Baroni, Maria Cristina Salvatore, Aldino Bondesan, Carlo Brabante
ISSN 2224-0020 (online); ISSN 1022-8136 (print)
Creative Commons License -CC BY-NC-ND 4.0
|Powered by OJS and hosted by Stellenbosch University Library and Information Service since 2011.
This journal is hosted by the SU LIS on request of the journal owner/editor. The SU LIS takes no responsibility for the content published within this journal, and disclaim all liability arising out of the use of or inability to use the information contained herein. We assume no responsibility, and shall not be liable for any breaches of agreement with other publishers/hosts.


text:
We use cookies to help provide and enhance our service and tailor content and advertisements. Disable them / read more. By continuing or closing this message you agree to the use of cookies.
South Korea's shareholder activism revolution remains stuck in the slow lane
22 March 2019. By Jason Booth.
This year's proxy voting season was supposed to be a watershed for South Korean corporate governance, with 11 companies targeted for activism, versus just two in 2018. But with Elliott rejected by Hyundai Motor shareholders and KCGI, Korea's biggest activist fund, blocked from submitting proposals at next week's Hanjin KAL vote, it appears activism in Korea will only advance at a pace dictated by Korea's financial establishment.
In Seoul on Friday, shareholders for carmaker Hyundai Motor and affiliate car-parts maker Hyundai Mobis resoundingly rejected Elliott's call for a combined 7 trillion won ($6.15 billion) in dividend payouts and five board seats.
Failure of the dividend proposal was not unexpected. It had been publicly opposed by Korea's National Pension Service (NPS) and several international pension funds that were swayed by Hyundai's promise of a smaller, yet significant, dividend, as well as by arguments that the company needs to invest more in automotive technology related to electric and self-driving cars.
Mobis disappoints
But the failure to win any board seats, especially at Mobis, was a disappointment. Elliott's proposals to expand the Mobis board from nine to 11 seats and to add two independent directors were widely supported by international funds, including CalPERS and CalSTRS, as well as by proxy advisory firms Institutional Shareholder Services and Glass Lewis. Elliott's Mobis nominees reportedly won support from around 25 percent of voters.
Importantly, the Mobis proposals were opposed by Korea's NPS despite Elliott's efforts to win over the influential pension fund.
Friday's vote sets the stage for Elliott's next effort to influence an anticipated vote on the broader restructuring of Hyundai Motor Group, which includes Hyundai Motor and Mobis. Possibly referring to that vote, Elliott said in a statement it was encouraged by the shareholder support they did receive Friday and expressed confidence that "the future holds further improvements at Hyundai."
KCGI shot down
A possibly more significant setback for Korean shareholder activism was a court ruling Thursday preventing Seoul-based fund Korea Corporate Governance Improvement (KCGI) from submitting proposals for a March 29 vote by shareholders of Hanjin KAL, which owns Korean Airlines. KCGI is seeking the right to select two outside board directors and one auditor, and to limit salaries for board members.
Upholding a lower court ruling, the Seoul High Court sided with Hanjin KAL in its argument that KCGI had not met a requirement under the Commercial Act that an investor must hold a company's stock for 6 months prior to making such proposals. KCGI disclosed its investment on Aug. 28 and announced its proposal on Jan. 31.
KCGI had countered that it met another Commercial Act rule which states that a shareholder with more than a 3 percent stake can exercise their shareholder proposal rights until six weeks before a regular general meeting, citing a 2004 precedent.
The Seoul High Court's ruling has significance beyond Hanjin KAL as it effectively rules out the event-driven activism commonly practiced in the US, where funds initiate stakes in companies following market-moving events such as earnings restatement or merger announcements and then agitate for changes.
If held to the same standard, current proxy contests in the US such as Starboard Value's opposition to the merger of Bristol-Myers and Celgene or BlueMountain's campaign for board seats following the bankruptcy of PG&E would be impossible.
Dalton diplomatic
The next vote to watch will be Hyundai Home Shopping (HHS) on March 28, which is under pressure from Los Angeles-based fund Dalton Investments.
With more than 20 years' experience in Korea, Dalton appears to be taking a slower, more diplomatic approach than Elliott. Rather than make formal proposals for shareholder consideration, it has only announced its objection to the appointment of two independent directors and two audit committee members proposed by the company's board.
Dalton noted that all of the 146 voting items presented at HHS's board meetings last year were approved unanimously by every attending independent director.
Despite the announcement, and a broader publicity effort by Dalton to educate the Korean public and policymakers on the benefits of good corporate governance, people close to the campaign are not optimistic that the annual general meeting will lead to significant changes, MLex has learned.
NPS sets pace
Ironically, the only significant corporate reshuffle that may resulting from this year's proxy season in Korea could be forced by NPS, the national pension fund that helped scuttle Elliott's campaign at Hyundai.
The fund has put forward a motion for the dismissal of Suk Tae-soo, the president of Hanjin KAL, who faces allegations of breach of trust and embezzlement, along with one director. Unlike KCGI, the Seoul High Court has allowed NPS to proceed with its campaign against Hanjin KAL.
It indicates that the pace and direction of governance in Korea will not be decided by international activists, or even domestic ones, but by the quasi-governmental financial institutions that have continued to support the nation's family-controlled corporation, known as Chaebol, despite evidence that their dominance of the economy and stock market undercuts Korean investors, including the national pension fund itself.
At MLex we take your privacy seriously. As detailed in our Privacy Policy we will use your personal information to administer account and provide the products and services that you have requested from us.
MLex Limited and our LexisNexis Legal & Professional group companies may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center. You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy.
You'll be able to update your communication preferences any time by clicking here or via the unsubscribe link provided within our communications.


text:
Winifred Age: 23. I'm submissive and i like rough sex with domination from men.Peace and love to everyone call me to have those wild thoughts tamedWant this girl?
She rides my dick like there's no tomorrow - kinkycouple
Grace Age: 33. If you like, i can visit you now, but you also can come to me and we can have fun here.Send message
Amateur Babe NoFaceGirl Rides Her Man Passionately in Reverse Cowgirl.
Babysitter is worried.
Awesome handjob from my roommate girl - Solazola.
Italian Old Man With Large Cock Fucks A Young Lady.
Description: 7 minutes #1 of pussy: I play with my fingers - large labia - SOLVEIG. Big Clit Compliation.
Views: 1422 Date: 2018-11-05 Favorited: 5
User Comments 1
No comments...


text:
Hide Forgot
From Bugzilla Helper:
User-Agent: Mozilla/5.0 (X11; U; Linux i686; en-US; rv:1.7.7) Gecko/20050416 Fedora/1.0.3-2 Firefox/1.0.3
Description of problem:
When in xwindows my mouse stops responding. /var/log/messages reports "kernel: psmouse.c: TouchPad at isa0060/serio4/input0 lost sync at byte 1" . My hardware is a HP Evo N800c.
Version-Release number of selected component (if applicable):
How reproducible:
Steps to Reproduce:
1. Just use xwindows for between 1-5 hours and it eventually stops working
Actual Results: Mouse stops at current location and wont move. The mouse always appers to be a carrot (I hope I have the terminology right it's the same when on an textbox in the browser).
Additional info:
Mass update of -test bugs to update version to fc4.
(Please retest on final release, and report results if you have not already done
[This comment has been added as a mass update for all FC4 kernel bugs.
If you have migrated this bug from an FC3 bug today, ignore this comment.]
Please retest your problem with todays 2.6.12-1.1398_FC4 update.
If your problem involved being unable to boot, or some hardware not being
detected correctly, please make sure your /etc/modprobe.conf is correct *BEFORE*
installing any kernel updates.
If in doubt, you can recreate this file using..
mv /etc/sysconfig/hwconf /etc/sysconfig/hwconf.bak
mv /etc/modprobe.conf /etc/modprobe.conf.bak
Thank you.
not reproducable under FC4 release. Please close.


text:
21st CCLC for Virginia
This content was COPIED from BrainMass.com - View the original, and get the already-completed solution here!
I need information about required reports or audits of an existing grant at the school.
Outline the following:
•What are the requirements of the report or audit?
•What are the timelines and reporting periods—such as quarterly, semi-annually, or annually—that must be followed?
•What consequences are imposed by the granting agency if reports are late or inaccurate?
•How is the information to be presented in the report or audit gathered and tracked? What systems are in place at the school to have this information available when needed?
•What staff members, other than the preparer of the report, are involved in providing information and data? How are these people made aware of the reporting or auditing requirements? How are they involved in its preparation?
•Who authorizes the final submission?
•What legal and ethical obligations do you face in managing the allocation of these funds?
The schools here are closed for winter break and I am not able to interview school principal, grants manager, or internship site supervisor. Would you please help me? I need to write 1,000- to 1,250-word overview of the experience and your analysis based on these questions.© BrainMass Inc. brainmass.com October 10, 2019, 7:06 am ad1c9bdddf
Solution Preview
Alright, I have been working on this off and on for the past day. The grant I looked at was the 21st Century Community Learning Centers Grant (21st CCLC) for schools in Virginia. This is a grant awarded to the stated by the federal government, and then the states give funds to certain school districts. The funds are to implement a 3 year program to enrich before and after school programs.
The requirements of the reports depend on which report is being submitted. There are three main different kinds of reports. There is the General Monitoring Document (GMD), which is due between March and May. This document is only required for schools within certain districts. This document requires information on program information, verification of submission of other reports, perceived strengths, staff interaction information, and perceived challenges. There is also the On-Site Monitoring report. This report is completed by the University of Memphis' Center for Research in Education Policy (CREP) and is due between April and June. The ...
Solution Summary
An overview of required reports for the 21st CCLC grant for Virginia.


text:
Tara Fly
About Tara:
Tara Fly wanted to be a cat when she grew up. Instead, she became a crazy cat artist, obsessed with re-telling classic stories from a feline perspective through her artwork.
"Jane Austen wrote (in Pride & Prejudice): 'The more I see of the world, the more am I dissatisfied with it; and every day confirms my belief of the inconsistency of all human characters' ….. and thus, I paint CATS!"
She works in acrylics, using many thin layers in a technique similar to oil painting, onto stretched canvases and primed Masonite wood panels.
Tara has exhibited her artwork in group shows at the Washington County Arts Council, at the former Eight & Sand Gallery in Seattle, WA, and abroad in galleries in Scotland and Portugal. In addition to her originals available at the Co-Op gallery, she sells reproduction prints at the local cat adoption center, Give Purrs A Chance. Tara participates in several art festivals in the tri-state area, and donates paintings to an annual art auction held in Hagerstown, MD, ("Art For the Animals") to benefit local animal charities. She also accepts a few privately commissioned portraits each year.
She has been interviewed by award-winning Catster Magazine (formerly Cat Fancy), and by the local Hagerstown Business Magazine. She manages the Co-Op Gallery website.
A 1998 graduate of Berkeley Springs High School, Tara currently lives in Hagerstown, with her husband and children, four feline overlords, and a canine servant.


text:
A Glossary of Baby Safety Terms and Definitions For Your Peace of Mind
You love your baby of course, and therefore want to keep him or her safe. But it is a 24 hour a day duty, being concerned with the welfare of your new arrival. And being confused about something or other doesnt help your nerves at all. Hopefully youre already getting lots of help for this task whenever you need it, which everyone does once in a while, and here is a bit more now. Below is a list of some important words and phrases that are relevant to this topic but maybe youre not so sure about the meanings of:
So hopefully that list will be of help to you. Theres certainly a lot of things to think about where the safety of your baby is concerned, and dont forget to make sure they have their vitamins as they continue to grow, but nowadays in the western world; babies are safer and healthier on average than ever before in the history of humanity. So dont fret too much and make yourself ill in the process!
About The Author
Matt Jacks is a successful article writer for hire providing tips and advice for consumers purchasing or comparing camera monitors for babies, baby car seats and designer baby clothes & bedding. His numerous articles offer moneysaving tips and valuable insight on typically confusing topics.
This "Glossary of Baby Safety Terms & Definitions" reprinted with permission.
Other Interesting Topics
[ View Entire Index ] [ Reprint Rights ]


text:
Category / / Communications / blog / Design and Creative / Print / Uncategorized / Websites
Cooking up a Storm – The Committee
Last weekend I decided to pay a long awaited visit to my parents. Having not been there in nearly a month (which I knew I was going to get it in the…19th November 2015
Talking but Not Screaming – Five Tips For Marketing Your Small Business
When you run a business, you are often pulled in several different directions at once. Despite your best efforts, things seem to go from zero to a hundred miles an hour in…18th September 2015
How 'Small' Business Can Do 'Big' Marketing.
We have been very successful here at Nutshell Creative. We work with some pretty big names, and of course we are very proud of our client list because that is the best…11th August 2015
Premier League Reading Stars
Here at Nutshell, we're big believers in the power of the visual image and the written word. And when we get the opportunity to combine our passion for these with two other…19th March 2015
Offline vs online: How to get personal with your print
There is often a misconception from marketers around what personalisation actually means. It's not just about adding a customer's name to the top of the email or piece of direct mail –…1st December 2014


text:
1.1. Audience
This guide is aimed at system administrators who are capable of connecting to remote systems such as G Suite for Business and Office 365 Admin Panel. Mail routing is usually a detailed setup that requires a high level of competence and experience with mail servers.
Although we provide support for our own products, we do not provide support for third party products such as PowerShell or server administration of Google or Exchange.
If you are concerned you might have any difficulty completing these steps, please consider a solution with our consulting team, contactable via email@example.com. This will ensure a fast, cost-effective and stress-free implementation.
1.2. Using this guide
This guide provides steps for setting up mail routing using the Cloudiway platform, as well as details of any remote system configuration required. It uses the domain drypizza.com as an example of mail routing between Office 365 tenants. It also uses warmsushi.com as an example of a non-Office 365 system.
The screen dumps used in this guide reflect these business names to provide typical examples of data to enter into each field.
Whitepapers and guides covering Cloudiway's other products, such as general mail migration, are available from the Cloudiway website (www.cloudiway.com).
Cloudiway's mail routing migration solution helps businesses implement elaborate mail forwarding systems through a simple SaaS interface. As a result, mail routing with Cloudiway requires no additional software installation or overhead. You simply need to point your MX records to Cloudiway's mail routing platform and/or set up a smart host agent.
In addition, the Cloudiway mail routing platform is flexible, so mail migrations can be performed before, during or after mail routing, depending on your system setup and business requirements.
Regardless of the approach, all mail routing via the Cloudiway platform can be achieved without interruption to the end user.
2.1. Will mail routing work with my systems?
Mail routing can take place from any remote server that works on the application layer protocol (SMTP) to Office 365, Gmail or Exchange On-Premises. It can also take place between any of these services.
If you are using Exchange On-Premises 2010 or any other system, please get in touch with our technical consultants at firstname.lastname@example.com to discuss how mail routing can be implemented with your combination of remote systems.
Mail routing can also be a long-term solution, providing one aspect of enterprise coexistence (along with free/busy calendar synchronization and global address list synchronization, both explained later in this chapter), or it can be a short-term solution during a transition involving mail migration. Two of the most common mail routing scenarios are discussed in detail below.
2.2. Scenario 1: Mail routing during cutover mail migration
A cutover mail migration is a strategy normally completed over a single weekend. This one-shot approach is the simplest method of mail migration, and therefore the most popular choice.
After a cutover migration, many businesses need to update their domain names at their new mail system to match their previous system. However, moving domains from Office 365 tenants can take up to 48 hours. During this time, domains are unavailable. As a consequence, emails sent to users in those domains will result in non-delivery reports. Cloudiway's mail routing platform can be used to prevent delivery failures during the transition, ensuring all incoming mail is routed to the intended user regardless of the status of the domain.
The following diagram is an example of cutover migration between two Office tenants. Prior to migration or mail routing, when a mail was sent to email@example.com, it was delivered to the old office 365 tenant, which was associated with the domain name drypizza.com.
This changes during mail routing (when the process can begin to detach drypizza.com from the old tenant). A new mail sent to email@example.com will be routed to the Cloudiway platform. In the example below, Cloudiway will then redirect mail to the old tenant (dp.onmicrosoft.com), changing only the 'to' header in the original email message. Other paths are possible, but we recommend this one.
Note that Bob can reply to the email, but it will be sent from email@example.com because outbound mail is not set up for short-term cutover migrations (and drypizza.com has begun being detached, so it's no longer available). To avoid this situation and other similar situations, Cloudiway recommends that you keep mail flow pointing to the old tenant (as shown above) and perform a cutover during non-working hours.
2.2.1. Benefits
As well as the seamless delivery of mail offered by Cloudiway mail routing, using the service during a cutover mail migration has the following benefits:
2.2.2. Considerations
The TTL ('Time To Live' setting) of your DNS MX records may maintain cache. The issue may be addressed by decreasing the value of the TTL to the allowed minimum. The TTL is displayed in seconds, so 3600 is equal to 1 hour, for example. The minimum is often 15 minutes, which is equivalent to 900 seconds.
2.3. Scenario 2: Mail routing during staged migration
A staged migration allows you to migrate batches of mailboxes over the course of a few weeks or months. During the process, your messaging system is subjected to constant variations. For example, user mailboxes might be created or deleted; or some DNS domains might be added or depreciated.
The Cloudiway platform provides the redirection of incoming emails to the correct mailbox regardless of its migration status (inbound service).
The diagram below shows a typical migration from Gmail to Office. A non-migrated user, firstname.lastname@example.com, continues to receive new mails in her inbox at the old Gmail tenant. A migrated user, firstname.lastname@example.com, will now receive emails sent to firstname.lastname@example.com at the new Office 365 tenant.
The Cloudiway mail routing platform also performs proxy server services, and rewrites any From mail headers to match the business needs and system setup (outbound service). This means that Bob can continue to send emails as email@example.com until mail routing is deactivated.
2.3.1. Benefits
As well as the seamless delivery of mail offered by Cloudiway mail routing, using the service during batch migrations has the following benefits:
Please note that the Cloudiway mail routing platform does support TLS/SSL encryption.
2.4. Scenario 3: Mail routing during enterprise coexistence
Enterprise coexistence allows businesses to work as one company and is often used during mergers and acquisitions, and sometimes indefinitely if the business need requires it.
The coexistence platform is made up of three tools
2.4.1. Calendar free/busy
Cloudiway provides a coexistence tool for calendar free/busy time display. For example, a G Suite user on one can check the free/busy time of an Office 365 user. Coexistence manages cross-platform communication with no impact on the end user. It provides a seamless connection between two or more different remote systems during migration.
Calendar free/busy synchronization works between any mix of Office 365 tenants, G Suite and Exchange On-Premises.
2.4.2. GALsync
GALsync stands for global address list synchronization, allowing automatic updates between global address lists to ensure they remain synchronized. GALsync works between multiple address books through a simple configuration online, which sends pull requests to other address books configured for communication. When mail routing is used during long-term coexistence, this ensures that all address book updates, such as new users, deleted users, or users with changed details, are propagated to all other address books configured for GALsync.
More information about each of these products is on the Cloudiway website at www.cloudiway.com. To discuss any of these tools further, please get in touch with your existing Cloudiway contact, or via email@example.com.
For more information about security, please refer to this article.
4.1. Before you start
Before you start, please ensure you have the details outlined in the following table.
|Cloudiway login
|Stores details and provides communication between the systems you already use.
|Knowledge base access
|Our extensive knowledge base is always accessible, with videos, troubleshooting tools, samples and more.
|Decreased TTL of DNS MX records
|If inbound mail routing is part of your business need, ensure the TTL of each MX record is set to the minimal value: this reduces caching time when you will switch your MX records.
|Your domain provider.
4.2. Contact Cloudiway
Mail routing requires some configuration by your Cloudiway contact email@example.com, so you will need to get in touch with Cloudiway at the start of your project. A Cloudiway consultant will add the mail routing add-on to your project account and will work with you to setup the mail routing.
Follow the scenario sections below to suit your situation:
Scenario 1 Short-term domain transformation configuration (maximum around 48 hours).
Scenario 2: Longer-term domain routing (during batch migration or coexistence), using inbound or outbound rules or both, with the option of creating rules for individual users.
4.3 Scenario 1: Short-term domain transformation configuration
The Relay section of the Cloudiway mail routing platform is the simplest form of mail routing. It's used for inbound, short-term mail routing only, such as when moving a domain between Office 365 tenants, which normally takes up to 48 hours, and when no changes to usernames are required.
For longer term or more involved mail routing, skip these steps and go to section 4.4.
There is no user list associated here. If you need to make username changes, please contact Cloudiway, or follow the next sections instead. Otherwise, you can skip to section 4.4.
4.4. Scenario 2/3: Setup inbound and/or outbound mail routing rules (domain level)
The Cloudiway mail routing platform can work as an incoming or outgoing mail server for any domain. Setting up routing rules will ensure that all users within one domain have their mail routed. However, if any mail alias changes are required (ie, the prefix before the @ symbol in an email address), it's imperative that users are added to the user list on the Cloudiway mail routing platform. The steps are covered later in this scenario. The steps below cover the domain level.
To use inbound mail routing, simply follow the steps below to configure the Cloudiway platform, then add your users and point your MX records to the Cloudiway mail routing server (covered in later sections). You can have as many inbound mail rules as you need for multiple domains and multiple Office 365 tenants.
Outbound mail routing is setup in exactly the same way on the Cloudiway platform, so you can follow the steps below if your mail routing scenario requires outbound mail routing. You can have as many outbound mail rules as you need for multiple domains and multiple Office 365 tenants. Remember that when configuring outbound mail routing, the 'original' email domain or sender will be the address you wish to rewrite, rather than your preferred domain name.
4.5. Scenario 2/3: Setup inbound and/or outbound mail routing rules (user level)
If your mail routing needs don't involve any mail alias (username@) changes, the Cloudiway mail routing platform will use any domain level rules you've already setup to blanket route mail (for example, from *@youroriginal.domain to *@yournew.domain).
However, if any mail alias changes are required, they will need to be added to the mail routing user list. The Cloudiway mail routing platform will first check this user list before redirecting any incoming mail or rewriting any outgoing mail. If it finds a mail alias, it checks the updated mail alias and routes mail accordingly (for example, if email@example.com is listed with an updated email address of firstname.lastname@example.com, email will be redirected to firstname.lastname@example.com). If it doesn't find an entry for email@example.com, it will check the server level routing rules and, using the examples in this guide, redirect email to email@example.com.
Note that if outbound mail from Bob's new alias (email@example.com) still needs to look like it's coming from firstname.lastname@example.com, this it should be listed in the Outbound user list too. The source in this case would be email@example.com with a target of email@example.com.
Users added to the mail routing user list do not require a license.
There are two ways to add users to the mail routing user list. These include:
4.5.1. Option 1: CSV import
If you have a CSV file of users affected by username changes, you can upload the file to Cloudiway. The file must have the following fields in the header row, ';' is used as a field separator:
When uploading a CSV file, please note that any existing users will be overwritten. Therefore, once you have users in your user list, make sure you export the existing user list via the Users, Export UserList command on the Action bar before re-uploading the exported CSV file.
4.5.2. Option 2: Single user creation details
If you only need to add a new user or change just one or two users in your mail routing user list, you can use the single creation tool directly on the Cloudiway platform to save time. No need to export your existing CSV list, edit and re-upload!
Currently, existing users cannot be edited, so if you wish to update an existing user, make sure you delete the user first by selecting the checkbox beside the username and using the Users, Delete User(s) Mapping command from the Action bar.
4.6. Activate the Cloudiway mail routing service
Now is a good time to double-check that your mail routing configuration on the Cloudiway platform matches the scenario you wish to achieve. If everything looks correct, you can activate the mail routing service.
Activating the service doesn't mean that mail routing will begin right away. For incoming mail routing, you need to point your MX records to the Cloudiway platform. For outgoing mail, you must configure your remote system or systems to first reroute outgoing mail to Cloudiway (see the following sections).
Using the Push command on the Cloudiway platform will launch an asynchronous update job, and when the update is complete, you will receive a confirmation email in the inbox associated with your Cloudiway account. This means that mail routing on the Cloudiway side has successfully activated.
Mail routing will normally commence right away, and you will receive a confirmation email at the email address associated with your Cloudiway account. If you haven't received the confirmation email within two hours, please open a ticket via http://support.cloudiway.com.
If your business requirements include outbound mail routing, you will need to follow the sections below to ensure that your remote systems are setup to route emails via the Cloudiway platform, to allow for the email addresses and any From headers to be rewritten.
5.1. Before you start
Before you start, you will need to ensure you have the details outlined in the following table. As a courtesy, this guide provides remote system configuration details for the most popular mail systems — Office 365/Exchange and Gmail. If you use a different system and need help, consider engaging a Cloudiway consultant.
|Knowledge base access
|Our extensive knowledge base is always accessible, with videos, troubleshooting tools, samples and more.
|Google Admin console
|If Gmail is to be used as part of a mail routing setup, this is where the outbound mail configuration is set by a system administrator.
|Office 365 admin account
|If Office 365 is to be used as part of a mail routing setup, this is where the outbound mail configuration is set by a system administrator.
|Domain provider admin account
|This is required for access to change MX record to point to the Cloudiway servers (inbound flow or domain detaches).
5.2. Inbound routing: Update your MX records
If your mail routing scenario uses inbound mail routing, you must point your DNS MX records to the Cloudiway mail routing service before mail routing can commence. If you haven't already, make sure you decrease the TTL of each MX record to the minimal value, so that there will be no caching issue when you will switch your MX records. You should already have the Cloudiway mail routing service's address, so point your MX records to this when you're ready to begin inbound mail routing.
5.3. Add the Mail Routing Server IP as an allowed IP address
To avoid having the incoming emails arrive in your spam folder, you have to add the mail routing server IP address as an allowed IP address in your target tenant. To do so follow the steps below:
5.4. Outbound routing: G Suite — Configure your outbound flow
This section only applies if you're using G Suite for outbound mail flow. For routing outbound mails, or rewriting From mail headers, you will need to reroute your mail flow to use Cloudiway's mail routing service.
Once you have heard back from Cloudiway and have the outbound gateway for details for mail routing, you can begin configuration.
5.5. Outbound routing: Office 365/Exchange — Configure your outbound flow
This section only applies if you're using Office 365 or Exchange On-Premises for outbound mail flow. For routing outbound mails, or rewriting From mail headers, you will need to reroute your mail flow to use Cloudiway's mail routing service.
Once you have heard back from Cloudiway, you should have the outbound gateway details for mail routing, which means you can begin configuration.
5.6. Outbound routing: Add an SPF record to your DNS
An SPF record (Sender Policy Framework record) identifies which mail servers are allowed to send email on behalf of your domain. This prevents spammers from sending messages with forged From addresses at your domain.
An SPF record to each domain involved with mail routing is therefore is required before mail routing can begin. This ensures that the Cloudiway mail routing service is not blacklisted, avoiding delays and downtime. When adding each SPF record, use the same Cloudiway IP or domain name given to you for creating the external connector or outbound flow.
6.1. Check logs
The Cloudiway mail routing platform provides a text log of actions performed. You can check it at any time from the Relay, Inbound or Outbound areas of the platform but clicking on the Logs sub-menu.
6.2. Stop mail routing
When you're ready to stop using Cloudiway's mail routing service, follow the checklists below.
For inbound mail:
For outbound mail
Cloudiway provides an extensive knowledge base with many resources, including common error messages, video guides and downloads.
Please visit the mail migration knowledge base area here:
Please visit the entire knowledge base here (where you can search for keywords or read through topics): http://kb.cloudiway.com/
The knowledge base also contains information on how you can ask for further support, should you require it.


text:
POTD: 'Modern Family' Flashes Back 10 Years to the First Cast Table Read
Posted on Monday, August 5th, 2019 by Ethan Anderton
Modern Family is coming to an end with the final season premiering this fall. In honor of the show's upcoming conclusion, ABC flashed back to the first photo of the entire cast of the comedy when they assembled for the show's table read and juxtaposted it with the cast together for the final first table read for the last season. Check out the Modern Family flashback photo below. Read More »


text:
Pistachios in the News!
Looking for tips to stay healthy this holiday season? You've come to the right place. With the Thanksgiving holiday upon us and holiday parties filling our calendars, 'tis the season when healthy eating habits may fall to the wayside. But do not fret, as mindless eating can be deterred with a few healthy snacking strategies
Crack 'em, Chew 'em, Love 'em, Leave 'em: Let the Pistachio Principle be your guide! Empty pistachio shells may serve as a "visual cue" of how many pistachios you've consumed, so don't discard the shells after you've enjoyed the treat inside. Keep these two preliminary behavioral studies in mind next time you want a healthy holiday snack:
- Study participants who left pistachio shells on their desk reduced their calorie consumption by 18 percent compared to participants who discarded shells immediately after consumption.1
- People who consumed in-shell pistachios ate 41 percent fewer calories than those who consumed pistachios without shells.2 This suggests that empty shells may be a helpful visual cue as to how much has been eaten – thereby potentially encouraging reduced calorie consumption.
Good Things Come in Small Packages: Reduce the size of your holiday serving plates, bowls and glasses. When you eat from smaller dishes you may trick yourself into eating less, yet still feeling satisfied.
Snack Simply: Simple snack pairings are the easiest, and often, the most delicious. Pairing savory, crunchy pistachios with low-fat cheeses and seasonal fruits and vegetables is snacking you can feel good about.
Happy Heart, Happy Holidays: Pistachios are one of the lowest calorie and lowest fat snack nuts, making them a heart healthy snack choice. One to two handfuls of pistachios (1 ½ to 3 ounces) a day, as part of an overall healthy diet, may help to support cardiovascular health.
What are you thankful for this holiday season? Let us know on our Facebook page and be entered for a chance to win a case of pistachios! http://on.fb.me/19UMSkW
1. Painter, J. "The Effect of Pistachio Shells as a Visual Cue in Reducing Caloric Consumption." Appetite. 2011, 57(2):418-420.
2. Honselman, C.S., Painter, J.E., Kennedy-Hagan, K.J., Halvorson, A., Rhodes, K., Brooks, T.L., & Skwir, K. "In-shell pistachio nuts reduce caloric intake compared to shelled nuts." Appetite. 2011, 57(2):414-417.


text:
Australia (AUD)
One Brand, Two Stories. Learn more
One Brand, Two Stories. Learn more
We have a new Carhartt WIP website for customers in the US and Canada. Now offering domestic shipping and returns. Check it out.
Carhartt teamrider Joe Gavin now is part of the Landscape Skateboards team! Congratulations!
(Bastian Loewen)


text:
It's Friday, and you know what that means: a long weekend of doing absolutely nothing in bed. Nothing. Well, nothing but playing with gadgets. And thanks to our sponsors, we've got loads of them. Thanks Adobe, Ask.com, Atari, AT&T, Audi, Bank of America, Belvedere Vodka, Blu-Ray Disc Association, Canon, Casio, Evolve Speakers, Firefox, Ford Focus, HP, Helio, IBM, Logitech, Mio, The New York Times, Nikon, Nokia, OQO, Patron, Register.com, Ricoh, SanDisk, Sharp, Shure, Sonos, Sprint, Staples, SureFire, TiVo, T-Mobile, Toshiba, Toyota, Verizon, Vista, Wal-Mart and Zune.
[Join us]


text:
Here's a comment left by a visitor on my AOL Customer Service Phone Numbers and Contact Info page, who writes that by calling 703-265-1000 and leaving a voice mail message, he or she was "miraculously" able to cancel AOL:
After reading this web site I was finally able to cancel AOL and get them to cancel the continued billing for AOL. I'd had AOL for years but when my bank account was compromised and I got a new Visa number I was unwilling to give the number to a person in Romania who barely spoke English.
When I offered to give the number to someone in the US they refused. At that time I tried to cancel AOL. I was being billed monthly service fees but blocked from using AOL. As the monthly charges continued to increase the "total due", I was unable to cancel and convince them I had not been using AOL since they had blocked my usage.
Finally thru this site I called ….703-265-1000 and left a message on a voice mail. Miraculously I received a letter canceling all charges and finally terminating AOL.
Never give your full credit or debit card number to an AOL call rep.
You can change the way you pay for your AOL account online; just visit this page. It's better to keep your credit or debit card number to yourself than to give it to a call rep. All the same, the last rep this customer spoke to should've asked for the last four digits on the debit card to confirm the billing method, and from there should have canceled the account when asked to.
This customer was also blocked from using AOL. My take on it is the last call rep he or she spoke with knew that the billing method was in question and decided the account may have been compromised, too, so the customer was TOSed simply to protect the account.
Since the customer was still being billed monthly for a locked-down, unusable account, there was no choice except to contact someone higher-up at AOL; in this case, that meant calling AOL Corporate (the Corporate headquarters have moved from Virginia to New York in the last year; I assume calls are being re-routed).
I'm glad this story had a happy ending – but if you're having your own problems canceling AOL, please let me know.


text:
Already a member? Sign in here
| About Us
Come explore Tasmania, on Lonely Planet's "Top Ten Destinations in the World" List!
We are Ros and Rob, a retired professional couple interested in either holiday or longer term exchanges anywhere at anytime. We are most interested in Northern Territory, Queensland, Western Australia, NSW or Victoria. This is our second home so non synchronous exchanges are possible. International swap opportunities in Canada, USA, New Zealand, Spain and Italy are welcomed. We are easy going and spotlessly clean, we will treat your property with utmost respect and look after it like it is our own.
Warm, sunny, modern two bedroom beachouse. Direct access to pristine Sisters Beach within Rocky Cape National Park. Watch the waves roll onto the sand from the living area. Sisters Beach is one of Tasmania's most stunning beaches, in a totally pristine environment with amazing walking tracks, bike riding, kayaking and boating facilities. Enjoy long beach walks, amazing sunsets, fantastic bush walks, or bike ride through the national park enjoying the native fauna and flora. The beachouse has two bedrooms (quality beds, doonas, linen and electric blankets), wifi, a combined bathroom and laundry, large screen TV and fully equipped galley kitchen with quality appliances.
Sisters Beach is 20 minute drive from the Burnie Wynyard Regional Airport (1 hour flight from Melbourne international airport). Located in the beautiful Rocky Cape National Park (an Aboriginal Heritage Area), it provides a pristine environment which is excellent for sea and beach fishing, swimming, surfing, bike riding and bush walking. Unique and beautiful flora and fauna is plentiful in the national park. The pristine beaches and waters around Sisters Beach, Rocky Cape and Boat Harbour are magnificent. The water is turquoise, the sand is glistening white, a unique unspoiled paradise, home to a large pod of dolphins that can often be spotted close to shore. The NW Coast of Tasmania is a foodies paradise with farmers markets, fresh seafood and fantastic restaurants serving fresh local produce from one of the best agricultural areas in Australia.
Tasmania has been listed by Lonely Planet as of one of the top ten places in the world to visit, and the North West Coast is Tasmania's hidden gem. Kayaks, Bikes and boogie boards provided, plus a car by negotiation. Day trips to the beautiful Cradle Mountain and picturesque Stanley and Strahan villages are a must. The beautiful villages of Wynyard, Burnie, Penguin, Ulverstone, Devonport and Smithton are all within easy driving distance. The city of Launceston is a 2hr drive and the capital city Hobart is a 4hr drive.
Melbourne, Victoria, Australia
Open plan with large living areas at one of Port Phillip Bay's best beaches. Has hosted many family holidays and events....
read more
Christchurch, Canterbury, New Zealand
Comfortable, country living in lovely area with space to enjoy relaxing...
read more
Mandurah, Western Australia, Australia
Detached and private home located within Mandurah Quay Resort on the beautiful Peel Estuary. Our home backs onto the Len Howard Nature Reserve....
read more
(C) Copyright Itchyfoot Pty Ltd


text:
Hide Forgot
Description of problem:
yum miscalculates disk requirements when disk space is low:
Transaction Summary
Install 0 Package(s)
Update 52 Package(s)
Remove 0 Package(s)
Total download size: 76 M
Error Summary
Disk Requirements:
At least 5732MB needed on the /usr filesystem.
[root] xm-fc7-001 ~]# df -h
Filesystem Size Used Avail Use% Mounted on
1.9G 1.7G 119M 94% /usr
Version-Release number of selected component (if applicable):
How reproducible:
Run "yum update" with less space than required for updates.
Steps to Reproduce:
1. Run yum update with less space than needed for proper installation
Actual results:
yum reports that Disk Requirements are close to 6Gig whereas the proper number
is about 50M extra needed.
Expected results:
yum disk space number should be correct
Additional info:
Possibly related to bug id=209980
Created attachment 150636 [details]
full output from yum update
The problem is in in the wording of the problem.
The term "needs" is in the sense that "... needs an additional ..."
All other packages will report the same problem for a given mount point.
I'm not certain I understand... The /usr filesystem had 1.9G total, with 1.7G
used. There were 76M of updates. Yum is asking for 5732M (close to 6G) needed.
That's almost 4G more than needed.
I don't know where you are getting 5732M from.
What is being indicated is
1) You have 119Mb on /usr:
1.9G 1.7G 119M 94% /usr
2) You need an *additional* 182MB on /usr in order to run the transaction.
Transaction Check Error:
installing package glibc-common-2.5.90-19 needs 182MB on the /usr filesystem
The 5732M is what the error is. This number was reported by yum:
Error Summary
Disk Requirements:
At least 5732MB needed on the /usr filesystem.
Then this is a yum error. The correct answer is that an additional 182M is needed on /usr.
Please reassign this bug to yum.
Fedora 7 test bugs should be filed against "devel", not against test1/2/3. This
isn't obvious, I know. Moving this report so it isn't lost.
This is a bulk message -- I apologize if this was actually meant to be targeted
against a different release. If so, please fix or let me know. Thanks.
Closing, moving to devel #235892:
*** This bug has been marked as a duplicate of 235892 ***
Created attachment 158440 [details]
custom package, incase it matters.
Present on Fedora 7.
Another more extreme example:
# df -h
Filesystem Size Used Avail Use% Mounted on
# yum localinstall /usr/src/redhat/RPMS/i386/timms-global-0.0.2-5.i386.rpm
{own package that only has requires, no content}
Install 89 Package(s)
Update 1 Package(s)
Remove 0 Package(s)
Total download size: 697 M
{note: downloads and yum cache are on a different partition}
Is this ok [y/N]: y
Downloading Packages:
Running Transaction Test
Finished Transaction Test
Transaction Check Error:
installing package torcs-data-tracks-road-1.3.0-1 needs 104MB on the /
installing package ppracer-0.3.1-10.fc7 needs 1085MB on the / filesystem
installing package bitstream-vera-fonts-1.10-7 needs 1085MB on the /
Error Summary
Disk Requirements:
At least 57250MB needed on the / filesystem.
{ 57.25 GB ! to install ~1.5 GB of data.}